Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice  by Cozzoli, Anna et al.
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Inhibitors  of  angiotensin  converting  enzymes  (ACE)  are  clinically  used  to  control  cardiomyopathy  in
patients  of  Duchenne  muscular  dystrophy.  Various  evidences  suggest  potential  usefulness  of  long-term
treatment  with  ACE  inhibitors  to  reduce  advanced  ﬁbrosis  of dystrophic  muscle  in the  mdx  mouse  model.
However,  angiotensin  II  is  known  to exert  pro-inﬂammatory  and  pro-oxidative  actions  that  might  con-
tribute  to early  events  of  dystrophic  muscle  degeneration.  The  present  study  has  been aimed  at  evaluating
the  effects  of an  early  treatment  with  enalapril  on the  pathology  signs  of  exercised  mdx  mouse  model.  The
effects  of  1  and  5  mg/kg  enalapril  i.p. for  4–8  weeks  have  been  compared  with  those  of 1 mg/kg  -methyl-
prednisolone  (PDN),  as  positive  control.  Enalapril  caused  a  dose-dependent  increase  in fore  limb  strength,
the highest  dose  leading  to a recovery  score  similar  to  that  observed  with  PDN.  A dose-dependent  reduc-
tion of  superoxide  anion  production  was  observed  by  dihydroethidium  staining  in  tibialis  anterior  muscle
of enalapril-treated  mice,  approaching  the  effect  observed  with  PND.  In parallel,  a  signiﬁcant  reduction  of
the activated  form  of  the  pro-inﬂammatory  Nuclear  Factor-kB  has  been  observed  in gastrocnemious  mus-
cle.  Histologically,  5  mg/kg  enalapril  reduced  the  area  of  muscle  necrosis  in  both  gastrocnemious  muscle
and diaphragm,  without  signiﬁcant  effect  on non-muscle  area.  In  parallel  no  signiﬁcant  changes  have
been  observed  in  both  muscle  TGF-1  and  myonuclei  positive  to  phosphorylated  Smad2/3.  Myoﬁber
functional  indices  were  also  monitored  by  microelectrodes  recordings.  A  dose-dependent  recovery  of
macroscopic  chloride  conductance  has  been  observed  upon  enalapril  treatment  in EDL  muscle,  with
minor effects  being  exerted  in  diaphragm.  However  a  modest  effect,  if  any,  was  found  on  mechanical
threshold,  a functional  index  of  calcium  homeostasis.  No  recovery  was  observed  in  creatine  kinase  and
lactate  dehydrogenase.  Finally  the  results  suggest  the  ability  of  enalapril  to  blunt  angiotensin-II  depen-
dent  activation  of  pro-inﬂammatory  and  pro-oxidant  pathways  which  may  be earlier  events with respect
to the  pro-ﬁbrotic  ones,  and  may  in part  account  for both  functional  impairment  and  muscle  necrosis.
The  PDN-like  proﬁle  may  corroborate  the  combined  use  of  the two  classes  of  drugs  in  DMD  patients
so  to  potentiate  the  beneﬁcial  effects  at skeletal  muscle  level,  while  reducing  both  spontaneous  and
PDN-aggravated  cardiomyopathy.
© 2011 Elsevier Ltd. 
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Duchenne muscular dystrophy (DMD) is a genetic muscle dis-
order affecting 1 over 3500 male birth and is due to defects of Xp21
gene coding for dystrophin. Animal models do exist, such as the
mdx  mouse, which are important for pre-clinical studies of pathol-
ogy mechanisms and therapeutic approaches [1,2]. Dystrophin is a
subsarcolemmal protein providing a mechanical link between the
intracellular cytoskeleton and the extracellular matrix via the inter-
action with the dystrophin-associated glycoprotein complex. The
absence of dystrophin leads to a progressive muscle ﬁber death,
failing regeneration and ﬁbrosis, through a complex and not fully
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nderstood network of events. An early and chronic inﬂamma-
ory state plays an important role in degeneration–regeneration
vents and in the greater susceptibility to oxidative stress; also the
bsence of dystrophin leads to a dislocalization of nNOS, which
ontributes to an impaired vasodilatation in contracting mus-
les and possibly to the loss of calcium homeostasis [3–5]. All
hese events inﬂuence pathology presentation and progression. The
bsence of dystrophin in cardiac tissue leads to cardiomyocites
eath and ﬁbrosis with a clinical picture of cardiomyopathy and
ate heart failure. Cardiomyopathy is the cause of death in about
0–20% of DMD  patients, and requests speciﬁc pharmacological
anagement, among which drugs targeting the renin-angiotensin
ystem (RAS) such as angiotensin (Ang)-converting enzyme (ACE)
nhibitors [6,7]. Early treatment of DMD  boys with perindopril
efore the onset of cardiac involvement has been found to signif-
cantly reduce mortality for both cardiac and non cardiac events,
upporting the important therapeutic role of RAS-contrasting drugs
8,9]. Accordingly, multicentric clinical trials in DMD  patients with
ngiotensin (AT)-1 receptor antagonists vs. ACE inhibitors are
pcoming. In addition recent pre-clinical experiments on mdx
ice underlined the beneﬁcial effect of captopril vs. the dele-
erious action of prednisolone on heart function [10]. Inhibition
f RAS may  also support function and morphology of dystrophic
uscle. Cohn et al. [11], have demonstrated that a chronic 6–9
onths treatment with losartan, an inhibitor of AT1 receptor of
ng-II, signiﬁcantly reduces/prevents ﬁbrosis in skeletal muscle
f mdx  mice. In parallel, contractile function and histological pro-
le were ameliorated. In short term, losartan ameliorates muscle
egeneration potential of 9-month-old mdx  mice after cardiotoxin
njury. These effects have been directly attributed to the inhibi-
ion of TGF-1, the pro-ﬁbrotic cytokine involved in dystrophic
uscle ﬁbrosis, due to the documented ability of Ang-II to stim-
late TGF-1 production [12,13]. However, Ang-II may  also exert
GF-1 independent effects that can contribute to ﬁbrosis, to mus-
le degeneration and to impaired myoﬁber regeneration [12–14].
n fact Ang-II directly stimulates vasoconstriction and pro-ﬁbrotic
mad signaling and activates, via protein kinase C/NF-kB, the
biquitin-proteasome pathway; this latter is known to play a
ole in proteolysis occurring in dystrophic muscle [13–16].  In
ddition, Ang-II, via receptor-mediated pathways, enhances the
ctivity of NADPH-oxidase, leading to over-production of super-
xide anion, the main reactive oxygen species (ROS) produced
y the enzyme [17]. The Ang-II induced ROS-dependent signal-
ng may  in turn sustain inﬂammation, reinforcing NF-kB activation
nd production of pro-inﬂammatory cytokines [5,17,18]. Interest-
ngly, NADPH-oxidase seems to account for the oxidative stress in
eart and muscle of the mdx  mouse [19–22],  which in turn plays
n important role, via NF-kB, in degeneration of dystrophic muscle
4,23,24].
The present research has been focused at evaluating the
arly role of Ang-II in dystrophic muscle pathology and, conse-
uently, the usefulness of a timely therapy with RAS-contrasting
rugs against muscular, other than cardiac, impairment in DMD
atients. To this aim we performed a 4–8 weeks treatment with
he ACE inhibitor enalapril (1–5 mg/kg), during a stage of mdx
athology (from the 5th to the 12th weeks of age) in which
egeneration–regeneration cycles are prominent phenomena with
espect to ﬁbrosis. The treatment has been performed in the
odel of exercised mdx  mice, which shows an enhanced mechan-
cal and inﬂammation-dependent degeneration phase and also
n relation to the potential role of RAS in impairing exercise
erformance [25]. The effects were evaluated with a multidisci-
linary approach, on a large array of in vivo and ex vivo readout
arameters and compared with those produced by -methyl-
rednisolone (PDN), the gold standard for treatment of DMD
oys [7].esearch 64 (2011) 482– 492 483
2.  Materials and methods
All experiments were conducted in accordance with the Italian
Guidelines for the use of laboratory animals, which conform to the
European Community Directive published in 1986 (86/609/EEC).
Most of the experimental procedures used conform the standard
operating procedures for pre-clinical tests in mdx  mice available
on http://www.treat-nmd.eu/research/preclinical/SOPs/.
2.1. In vivo experiments
2.1.1. Animal groups, treadmill running and drug treatment
A total of 30 mdx  male mice of 4–5 weeks of age (Charles
River Italy-Jackson Laboratories, USA), and homogeneous for body
weight underwent a 30 min  running on an horizontal treadmill
(Columbus Instruments, USA) at 12 m/min, twice a week (keep-
ing a constant interval of 2–3 days between each trial), for 4–8
weeks, according to standard protocol [19,26]. The reason for
using the chronic treadmill exercise and the relative impact on
the murine pathology have been extensively described in previous
articles [26–29],  then minimizing the need of an additional con-
trol group of untreated non-exercised mdx  mice. Thus the groups
were as follows: 8 mdx  mice vehicle-treated, 7 mdx  mice treated
with enalapril at 1 mg/kg, 8 mdx  mice treated with enalapril at
5 mg/kg and 7 mdx  mice treated with prednisolone at 1 mg/kg.
Age and gender-matching wild type mice (wt, C57/BL10ScSn) were
also used for speciﬁc experimental purposes, as indicated in the
text. After reviewing the available information, the two doses of
enalapril (Sigma–Aldrich-Italy) were chosen in the medium-high
therapeutic range and after proper correction for mouse dosing,
so to better correlate with the dose to be used in DMD  patients
and to avoid false positive/negative [30–32],  while the dose of PDN
has been chosen based on our previous studies [27,28]. The treat-
ment started one day before the beginning of the exercise protocol,
and continued until the day of sacriﬁce. Each dose of any drug was
formulated by proper dilution in sterile water for i.p. injection, so
to have the desired drug amount in 0.1 ml/10 g body weight. Drug
free-animals were injected with equal amount of vehicle. Wild-
type mice were left free to move in the cage, without additional
exercise and monitored at the same time points of mdx  animals,
according to the experimental need. Every week all mice were
monitored for body weight and fore-limb force by means of a grip
strength meter (Columbus Instruments, USA); the end of the 4th
week was  considered for statistical analysis [19,28]. At this time, an
exercise resistance test on treadmill was  also performed. All mice
were made running on a horizontal treadmill for 5 min  at 5 m/min,
then increasing the speed of 1m/min each minute. The total dis-
tance run by each mouse until exhaustion was measured [19]. At
the end of the 4th week of exercise/treatment the ex vivo experi-
ments were also started. Due to the time-consuming nature of some
of the ex vivo experiments, no more than one-two animals could be
sacriﬁced per day. This required to prolong the experimental time
window. Thus, the animals continued to be exercised/treated until
the day of sacriﬁce but no longer than 8 weeks in total.
2.2. Ex vivo studies
2.2.1. Muscle preparations
Animals of 8–12 weeks belonging to the different groups were
anesthetized with 1.2 g/kg urethane i.p. Extensor digitorum longus
(EDL) muscle of one hind limb and right hemidiaphragm were
removed and rapidly placed in the recording chamber for the elec-
trophysiological recordings. Gastrocnemious (GC) muscles from
one side were removed and processed for histology procedures,
while the contralateral ones were snap frozen in liquid nitrogen
and stored at −80 ◦C until use for biochemical analysis. The same
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rocedure was used for the left half-side of diaphragm (DIA), while
A muscles were frozen in liquid-nitrogen cooled isopentane for
mmunoﬂuorescence studies.
.2.2. Electrophysiological recordings by intracellular
icroelectrodes
EDL muscles and hemidiaphragm strips were bathed at 30 ± 1 ◦C
n the following normal physiological solution (in mM):  NaCl
48; KCl 4.5; CaCl2 2.0; MgCl2 1.0; NaHCO3 12.0; NaH2PO4 0.44
nd glucose 5.55, continuously gassed with 95% O2 and 5% CO2
pH = 7.2–7.4).
Two intracellular microelectrode current clamp method was
sed to measure the membrane electrical properties of muscle
bers, among which membrane resistance (Rm), according to the
able equation (ﬁber input resistance of 140 and 200  cm2, for
DL and DIA, respectively) [26,28].  The total membrane conduc-
ance (gm) was calculated as 1/Rm in normal physiological solution,
hile 1/Rm calculated in a chloride-free solution was  the potassium
onductance gK. Chloride conductance (gCl) was calculated as the
ean gm minus the mean gK [26,28].
The mechanical threshold (MT) was determined in EDL mus-
le ﬁbers in the presence of tetrodotoxin (3 M)  using a two
icroelectrode “point” voltage clamp method [19,28]. In brief, the
wo microelectrodes (spaced about 50 m)  were inserted into the
entral region of a superﬁcial ﬁber, continuously viewed using a
tereomicroscope (100× magniﬁcation). Depolarizing command
ulses of duration ranging from 500 to 5 ms  (0.3 Hz) were pro-
ressively increased in amplitude from the holding potential (H) of
90 mV  until visible contraction. The threshold membrane poten-
ial (V, in mV)  was read on a digital sample-and-hold millivoltmeter
or each ﬁber at the various pulse durations t (in ms); mean values
t each t allowed the construction of a “strength-duration” curve.
heobase voltage (R, in mV)  and the rate constant (1/, s−1) to reach
he rheobase were obtained by a non-linear least square algorithm
sing the following equation: V = (H − R exp (t/))/(1 – exp (t/)),
here H is the holding potential (mV), R, is the rheobase (mV)
nd  is the time constant. In the ﬁtting algorithm, each point was
eighed by the reciprocal of the variance of that mean V and the
est ﬁt estimates of the parameters R and  were made [19,28].
.2.3. Histology and immunohistochemistry
Six-8 m sections of GC and hemidiaphragm muscles ﬁxed in
odiﬁed Bouin solution, were stained with toluidin blue which
llows to distinguish between healthy myoﬁbres (peripherally
ucleated ﬁbers), regenerating/regenerated myoﬁbers, showing
entral nuclei (centrally nucleated ﬁbers), degenerating ﬁbers,
ssociated to the presence of inﬂammatory inﬁltrate, as well as
he non muscle tissue (ﬁbrotic or adipose tissue). Morphometric
nalysis was performed on ten cross-sections from each exper-
mental group by means of at least three animals per group, by
able 1
ffect of enalapril treatment on body weight and fore limb muscle strength of mdx  mice.
Groups BW T0 BW T4 BW (T4–T0) Fmax T0 
WT (5) 19.7 ± 0.41 25.41 ± 0.8 5.7 ± 0.71 0.122 ± 
Mdx  + vehicle (8) 17.8 ± 1.24 22.3 ± 1.36* 4.48 ± 0.35 0.113 ± 
Mdx  + Enal 1 (7) 16.0 ± 0.71* 20.8 ± 0.57* 4.86 ± 0.54 0.106 ± 
Mdx  + Enal 5 (8) 18.8 ± 0.72 22.8 ± 0.59* 4.05 ± 0.77 0.122 ± 
Mdx  + PDN (7) 19.9 ± 0.99 23.3 ± 0.31 3.44 ± 0.88 0.107 ± 
olumns are as follows: Groups of mice used (in brackets the number of mice per group)
ith  enalapril 1 mg/kg (Mdx + Enal 1); Mdx  mice treated with enalapril 5 mg/kg (Mdx + En
 at the beginning (T0) and at the end of 4-week-protocol (T4); BW,  difference betwee
eginning (T0) and at the end of 4-week-protocol (T4); Fmax: fore limb strength increm
he  beginning (T0) and at the end of 4-week-protocol (T4). Each value is the mean ± S.E
y  ANOVA test for multiple comparison (F values) and Bonferroni t-test post hoc correct
 < 0.04); Fmax at T4 (F > 3; p < 0.05); NF at T4 (F > 4; p < 0.01). The Bonferroni’s test showed
WT  (0.002 < p < 0.04); §Mdx  + vehicle (0.002 < p < 0.01), #Mdx  + Enalapril 1 mg/kg (p < 0.01esearch 64 (2011) 482– 492
using an Image Analysis software (Olympus Italia, Rozzano, Italy)
[27,29].  For immunohistochemistry, GC muscles were ﬁxed in a
4% paraformaldehyde in phosphate-buffered saline (PBS), then
washed in PBS, dehydrated in an ascending ethanol series and
embedded in parafﬁn. Coronal sections of 5 m were collected on
polilysine coated slides, deparafﬁnized, rehydrated and rinsed for
10 min  in tris-buffered saline (TBS) pH 7.2. Endogenous peroxidise
was  blocked by incubation in 3% H2O2 dissolved in methanol for
45 min  in the dark. The sections were brought to a boil in 10 mM
sodium citrate buffer, pH 6, in the dark for 5 min, and after cooling
were treated with 5% horse serum in TBS for 1 h and then sequen-
tially incubated with (i) primaries rabbit anti-phospho-Nuclear
Factor(NF)-kB p65 subunit antibody (Cell Signaling Technology,
Inc., Celbio Italia) and with goat phospho-Smad2/3(Ser 423/425)
(Santa Cruz Biotecnology, Inc.) [29] both diluted 1:50 in TBS
overnight at 4 ◦C; (ii) secondary antibody, biotin-labeled swine
anti-rabbit IgG and biotin-labeled swine anti goat (Vector Inc.,
Burlingame, CA) followed by streptavidin-peroxidase conjugate
(Vector Inc.). The developing reaction was performed in 0.05 M
acetate buffer pH 5.1, 0.02% 3-amino-9-ethylcarbazole grade II
(Sigma Chemical Co.), and 0.05% H2O2. Sections were then washed
in the same buffer, counterstained with Mayer’s hematoxylin
for 1 min  and mounted in buffered glycerin. Negative controls,
obtained by substituting normal rabbit serum and normal goat for
the primaries antibodies, showed no staining of the sections.
Dihydroethidium (DHE; Molecular Probes Inc., USA) was  used
to evaluate superoxide (O2−) production in muscles in situ [19,22].
DHE freely enters cells where, in the presence of O2−, it is oxi-
dized to ethidium bromide that intercalates within nuclear DNA
and emits red ﬂuorescence in proportion to the amount of O2−
present (excitation at 488 nm,  emission at 610 nm). Unﬁxed, frozen
TA muscles were cut into 10-m-thick cross-sections. Sections
were pre-hydrated with PBS (10 min) and then incubated with DHE
(2 M,  30 min, 37 ◦C) in a dark, humidiﬁed chamber. Sections were
subsequently washed, stained with 4,6-diamidin-2-phenylindol
dichlorohydrate (DAPI, Santa Cruz Biotech, Inc., California, USA)
to visualize cell nuclei, and mounted on a coverslip. Results were
observed with an epiﬂuorescent Zeiss Axiovert TS100 microscope
with appropriate ﬁlters. Images were captured with a CCD cam-
era in conjunction with AxioVision Software (Zeiss) using identical
imaging settings for each image acquisition. Densitometric anal-
ysis for merging of DHE and DAPI ﬂuorescence was  performed
using AxioVision Rel 4.6.3 software. Fluorescence was quantiﬁed
by counting the number of pixels in identical ﬁelds for each group
and expressed as relative increase with respect to unitary value
from wt mice [19].2.2.4. Determination of transforming growth factor-ˇ1 (TGF-ˇ1)
TGF-1 protein was measured by enzyme-linked immunosor-
bent assay (ELISA), according to the manufacturer’s instructions
Fmax T4 Fmax (T4–T0) NF T0 NF T4
0.006 0.181 ± 0.01 0.058 ± 0.018 6.25 ± 0.4 7.09 ± 0.33
0.01 0.143 ± 0.01* 0.03 ± 0.009 6.29 ± 0.25 6.33 ± 0.34
0.009 0.148 ± 0.004* 0.042 ± 0.006 6.62 ± 0.49 7.15 ± 0.26
0.008 0.176 ± 0.004#§ 0.054 ± 0.007§ 6.49 ± 0.28 7.77 ± 0.22§
0.01 0.160 ± 0.01 0.050 ± 0.01 5.32 ± 0.38 6.86 ± 0.35§
: wild type C57BL10 (WT); untreated mdx  mice (Mdx + vehicle); Mdx  mice treated
al 5), Mdx mice treated with -methylprednisolone (Mdx + PDN); body weight, in
n body weights at T4 and T0; Fmax, maximal fore limb strength, in kg at either the
ent between T4 and T0. NF: fore limb strength normalized to body weight at either
.M. For each parameter, the statistical signiﬁcance between groups was evaluated
ion. Signiﬁcance at ANOVA test was found for the following parameters BW (F > 3;
 statistical signiﬁcance as shown in the table with respect to the following groups:
).
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R&D System, Minneapolis, MN,  USA). Brieﬂy, 10–20 mg  of tissue
as homogenized in 500 l of a solution containing 1% Triton X-
00, 20 mM Tris pH 8.0, 137 mM sodium chloride, 10% glycerol,
 mM ethylendiaminetetraacetic acid and 1 mM  phenylmethyl-
ulphonyl ﬂuoride [26]. TGF-1 levels were expressed as pg of
GF-1/g of total protein, measured by classical Bredford analysis.
.2.5. Creatine kinase and lactate dehydrogenase in plasma
nd/or bloodBlood was collected by heart puncture soon after animal death in
DTA/heparin rinsed centrifuged tubes. The blood was centrifuged
t 3000 × g for 10 min  and plasma was separated and immediately
sed or stored at −20 ◦C for less than one week. Creatine kinase and
ig. 1. Effect of enalapril treatment on fore limb strength and resistance to exercise
n  mdx  mice. (A) The bars show the normalized force increment ( normalized
orce) for wild type (WT) and mdx  mice either untreated (vehicle) or treated with
nalapril 1 mg/kg (Enal 1), 5 mg/kg (Enal 5) or -methylprednisolone 1 mg/kg (PDN).
 normalized force has been calculated as follows: for each mouse the fore limb
trength has been normalized to the respective body weight both at the beginning
f  exercise/treatment protocol (Time 0) and after 4 weeks (Time 4). The difference
etween the normalized strength values at the two time points allowed to calcu-
ate  for each mouse of each group the increment and to evaluate the effect of either
xercise, treatment or both on it. Each bar is the mean ± S.E. (see Section 2) from
he  number of mice in brackets above each bar. Statistical signiﬁcance between
roups was evaluated by ANOVA test for multiple comparison and Bonferroni t-
est post hoc correction and was as follows: F > 38; p < 0.0001; 10 < F < 40; p < 0.005;
igniﬁcantly different with respect to *vehicle-treated mdx  (p < 0.0001); §enalapril
 mg/kg treated mice (p < 0.0001). Although not shown in the ﬁgure, the values from
dx mouse groups were signiﬁcantly different with respect to those of WT mice. In
B)  is shown the total distance (in m)  run by wt and mdx  mice treated or not with
nalapril 5 mg/kg (Enal 5) or -methylprednisolone 1 mg/kg (PDN) in an exhaust-
ng test on treadmill. Each bar is the mean ± S.E.M. from 5 to 6 animals. Statistical
igniﬁcance between groups was evaluated by ANOVA test for multiple comparison
F  values) and Bonferroni t-test post hoc correction and was as follows: F = 11.03;
 < 0.0005; *signiﬁcantly different with respect to WT  mice (p < 0.005).esearch 64 (2011) 482– 492 485
lactate dehydrogenase determinations were performed by stan-
dard spectrophotometric analysis by using diagnostic kits (Sentinel,
Farmalab, Italy) [27].
2.3. Statistics
All data is expressed as mean ± standard error of the mean
(S.E.M.) or ±standard deviation (S.D.). The S.E. estimate for the
ﬁtted rheobase (R) values (and relative statistical analysis) were
obtained as previously described [28]. The size of the S.E. of nor-
malized strength increment (NF) has been calculated from the
standard error of the mean (S.E.M.) values of normalized strength
at each time, taking into account the size, as percent of the mean,
of each S.E.M. and considering the sum of them as indicative of
the maximal size of the calculated S.E. This approach allowed
to minimize the unpredictable variability due to differences in
absolute values of the individual differences [33]. Statistical anal-
ysis for direct comparison between two means was performed
by unpaired Student’s t test. Multiple statistical comparisons
between groups, were performed by one-way ANOVA, with Bon-
ferroni’s t test post hoc correction for allowing a better evaluation
of intra- and inter-group variability and avoiding false positive.
Pathology-related alterations in mdx  groups were detected as the
amount of signiﬁcant impairment with respect to wt  mice. The
recovery score by the drug treatment, as percentage of change
toward the wt value, has been evaluated according to the Stan-
dard Operating Procedures described in the Treat-NMD web site
(http://www.treat-nmd.eu/research/preclinical/DMD SOPs).
3. Results and discussion
3.1. Effect of enalapril on forelimb strength and resistance to
treadmill exercise
The body weight values at the beginning and at the end of the
in vivo phase, along with the 4-week increments, are shown in
Table 1. As can be seen, no signiﬁcant changes have been observed
in the increment over time in the various experimental groups,
although a slightly lower increment has been observed in enalapril
5 mg/kg and in the PDN-treated groups. A less increment in body
Fig. 2. Effect of drug treatment on weight of organs of mdx  mice. The ﬁgure shows
the  weight of EDL muscle, heart, spleen, liver and kidney of mdx  mice either
untreated (vehicle) or treated with enalapril 1 mg/kg (Enal 1), 5 mg/kg (Enal 5) or
-methylprednisolone 1 mg/kg (PDN). Each bar is the mean ± S.E.M. from 5 to 8 ani-
mals and show the organ values normalized with respect to the individual body
weight. When S.E.M. not visible is because lower than scale resolution. The normal-
ized values for the liver have been scaled by a factor of ten for graphical reasons.
ANOVA analysis and Bonferroni’s t test showed statistical differences only for muscle
weight (F = 4.7; p < 0.01) *signiﬁcantly different vs. mdx  vehicle-treated (p < 0.002).
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Fig. 3. Effect of drug treatment on superoxide production in TA muscle of mdx  mice. In situ detection of O2− in TA muscles was performed by visualizing red ﬂuorescence in
cell  nuclei of tissue sections loaded with DHE as described under Section 2. Representative ﬂuorescent photomicrographs from independent sets of experiments are shown
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and spleen) (Fig. 2), suggesting no gross toxic effects due to the
treatments.
Fig. 4. Effect of drug treatment on densitometric determination of superoxide anion
production. Densitometric determination of DHE ﬂuorescence in the nuclei of TA
muscles from mdx  mice treated or not with either enalapril at 1 (Enal 1) and 5 mg/kg
(Enal 5) or -methyl prednisolone (PDN) is shown. Each bar is the mean ± S.E.M. of
the value of ﬂuorescence relative to the merging of DHE (red) and DAPI (blue) stain-
ing  of wt  (arbitrarily considered as unitary) from analysis of 5–16 ﬁelds and 3–5or  TA muscle cross-sections at 10× magniﬁcation. Merging (magenta ﬂuorescenc
roduction in cell nuclei from mdx  mice either untreated (MDX + vehicle), or treate
nalapril  5 mg/kg (MDX + Enal 5).
eight with PDN has been also observed in other studies [27]. The
dx  groups showed slight but not signiﬁcantly lower values of
ore limb strength with respect to wt animals at the beginning
f the experimental protocol. In line with previous observations,
he maximal grip strength was signiﬁcantly lower after 4 weeks
f protocol in the vehicle-treated mdx  animals with respect to wt
nimals. The treatment with enalapril was protective, with a clear
ose-dependent effect on both the absolute value and its 4-week
ncrement (Table 1). On this latter the recovery score was 42% and
5% with 1 mg/kg and 5 mg/kg of enalapril, respectively. A similar
rotection has been observed with 1 mg/kg PDN (71%). In order to
ake into account the inter-individual inﬂuence of body weight, the
orelimb strength values were normalized to body weight both at
he beginning (time 0) and after 4 weeks (time 4) (Table 1). The nor-
alized force increment for each mouse over the 4 weeks was then
alculated as the difference (normalized force T4) − (normalized
orce T0) (Fig. 1A). Again, a clear dose-dependent increase in
ormalized strength increment by enalapril was observed; both
nalapril at 5 mg/kg and PDN showed increments in normalized
alues even higher than that observed in wt mice. To investigate
urther on the degree of functional amelioration by the drugs, an
cute test of resistance to treadmill exercise was performed at the
nd of the in vivo phase. As shown in Fig. 1B, the mdx  mice were sig-
iﬁcantly less resistant to exercise with respect to wt.  No signiﬁcant
mprovement in this parameter has been observed in both enalapril
nd PDN treated mdx  mice, although the enalapril-treated mice run
or a greater distance with respect to the other two  groups. In vivo
atigability of dystrophic animals is considered due to impaired
itric-oxide dependent vasodilatation [34]; the present results
uggest a partial role of Ang II-related vasoconstriction in poor
xercise-resistance of mdx  mice. Also, the results do not support
 role of RAS in the poor exercise performance of mdx  animals [25].DHE (red ﬂuorescence) and DAPI (blue ﬂuorescence) staining is indicative of O2
 -methylprednisolone 1 mg/kg (MDX + PDN), enalapril 1 mg/kg (MDX + Enal 1) or
Apart from a decrease in PDN-treated group, no signiﬁcant
differences were found in the weight of fast-twitch EDL muscle
between the experimental groups. Similarly, no signiﬁcant differ-
ences were found in the weight of vital organs (liver, kidney, heartmuscle per group (at 40× magniﬁcation). A signiﬁcant difference among groups
was  found by ANOVA analysis (F = 35.57; p < 0.0001), Bonferroni post hoc t-test
for  individual differences between groups are as follows: signiﬁcantly different
*vs. vehicle-treated mdx (p < 0.0001) and #vs. enalapil 1 mg/kg treated mdx  group
(p < 0.05).
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Fig. 5. Effect of enalapril treatment on activated NF-kB-positive myoﬁbers and histological proﬁle of mdx  mouse muscles. Upper panel: immunohistochemical expression
of  anti p65-phospho-NF-kB in gastrocnemious muscle ﬁbers of mdx  mice either untreated (+ vehicle) and treated with enalapril 5 mg/kg (+ Enal 5). The mdx  muscle shows
numerous positive nuclei in the peripherally and centronucleated ﬁbers, while enalapril-treated muscle show a reduced number of NF-kB labeled nuclei, mostly located
in  the centronucleated ﬁbers. Scale bar, 33.3 m.  Lower panel: Morphological features of gastrocnemius (GC) and diaphragm (DIA) muscles from untreated (A and C) and
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*nalapril  5 mg/kg treated (B and D) mdx  mice, by toluindine blue staining. The secti
ariability in ﬁber dimension, larger areas of necrosis accompanied by mononuclear
napril treated muscles showed a more homogenous architecture with less area of
.2. Effect of Enalapril on markers of oxidative stress and
nﬂammationEnalapril acts by contrasting the effects of Ang-II, which is
laimed to exert pro-oxidant and pro-inﬂammatory actions in
keletal muscle. In particular, Ang-II activates NADPH oxidase with
able 2
ffect of Enalapril treatment on histology proﬁle of diaphragm and gastrocnemious musc
% NF % CNF Area NF (2) 
GC Mdx  vehicle 28 ± 6.6 74 ± 7 832 ± 138 
GC  Mdx  + Enalapril 33 ± 2* 67 ± 6* 1141 ± 543 
DIA  Mdx  vehicle 52 ± 6 48 ± 6 699 ± 55 
DIA  Mdx  + Enalapril 46 ± 16 54 ± 4* 830 ± 108* 
he columns from left to right show the mean values ± S.D. obtained from at least 9 s
f  the normal ﬁbers while % CNF is the percent of centronucleated ﬁbers, i.e. regenera
egeneration–regeneration cycles in the muscle. Area of both normal ﬁbers (NF) and cen
bers  with a large inﬁltration of inﬂammatory mononucleated cells, while the % percent o
f  muscle ﬁbers that is not stained as muscular tissue and is composed by connective and
*p  < 0.001 and §p < 0.0001 vs. muscle-related vehicle-treated mdx  group.m untreated exercised muscles showed a less homogenous structure, with greater
ates and/or small regenerating ﬁbers. A areas of non muscle tissue are also present.
sis. Pictures at 20× magniﬁcation.
the production of superoxide anion [17]. Importantly, an overex-
pression of the muscular isoform of the NADPH oxidase, NOX2,
and an increased level of superoxide anion do occur in dystrophic
muscles [19–21].  In order to evaluate the potential anti-oxidant
effect of enalapril, we tested the ROS-sensitive dye DHE  on tibialis
anterior (TA) muscle. The speciﬁc ﬂuorescence was  evaluated by
le of mdx  mice.
Area CNF (2) % necrotic area % non-muscle area
1757 ± 453 5.7 ± 1.9 9.6 ± 3.2
1496 ± 316 1.2 ± 0.2§ 7.4 ± 4.6
1292 ± 219 8.1 ± 4.7 7.1 ± 3.5
1598 ± 226* 1.8 ± 0.7** 5.3 ± 2.4
ections from 3 preparations from each experimental group. % NF, is the percent
ted ﬁber which replace normal peripherally nucleated ﬁbers and are an index of
tronucleated ﬁbers (CNF). The % of necrotic area, is the area composed of necrotic
f non-muscle area, represents the area of space between ﬁbers or between groups
/or adipose tissue. Signiﬁcantly different by unpaired Student’s t test for *p < 0.05,
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Fig. 6. Effect of enalapil treatment on pro-ﬁbrotic signaling in mdx mouse muscles. The bars in the upper panel show the levels of total TGF-1 in gastrocnemius muscle,
measured by ELISA. Each value is the mean ± S.E.M. from 5 to 9 preparations. Statistical signiﬁcance has been evaluated by ANOVA and Bonferroni’t test post hoc correction
and  was as follows F > 10; p < 0.0001. *Signiﬁcantly different with respect to WT (p < 0.0001). The middle panel shows representative immunohistochemical expression of
p-Smad2/3 in gastrocnemius muscles ﬁbers of wt  (A), exercised mdx (B) and enalapril (5 mg/kg) treated exercised mdx (C) mice. No labeling of the nuclei and ﬁbers is present
in  wt  muscle (A), while the mdx  muscle shows numerous positive nuclei in the peripherally (B, arrow) and centronucleated ﬁbers (B, arrowhead). Enalapril-treated mice (C)
show  a general trend toward a reduced number of p-Smad2/3 labeled nuclei (scale bar, 33.3 m).  The quantitative estimation of positive myonuclei is represented in the
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tower  panel. The analysis (at least 3 animals/group and 9 ﬁelds/muscle; mean ± S.D.
roup  vs. vehicle treated one. Statistical signiﬁcance has been evaluated by ANOVA 
ifferent with respect to WT (p < 0.02).
he magenta merging of DAPI and DHE signals, indicating the spe-
iﬁc DNA binding of O2− activated dye. In line with previous data
19], a widespread and intense nuclear staining was observed in
dx  muscles (Fig. 3). Reactivity was observed in both myonuclei
nd in nuclei of non-muscle cells, likely inﬂammatory inﬁltrates. A
arked reduction of staining has been observed with both enalapril
 mg/kg and PDN 1 mg/kg. The densitometric analysis clearly evi-
enced a signiﬁcant and dose-dependent reduction of reactivity
oward the wildtype condition in the enalapril-treated animalsed only a slight not signiﬁcant decrease in pSmad2/3 reactivity in enalapril-treated
nferroni’s t test post hoc correction and was  as follows F > 7; p < 0.03; *signiﬁcantly
(Fig. 4). The effect by 5 mg/kg enalapril approached that observed
with PDN, suggesting a control of ROS production by enalapril
similar to that exerted by a classical anti-inﬂammatory approach
(Fig. 4). By the way, this is also the ﬁrst experimental proof that
PDN in fact reduces ROS production in dystrophic muscle.ROS are main signals for NF-kB activation and this latter is a
pro-inﬂammatory transcription factor claimed to have a key role in
muscular dystrophy [23,24].  Then, we performed an immunostain-
ing for the phosphorylated NF-kB p65 subunit, the activated form
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enalapril on pro-ﬁbrotic signaling, the percentage of myonuclei
positive to activated phosphorylated Smad2/3 was  estimated in
GC muscles. While almost no reactivity has been detected in wt
GC muscle, vehicle treated mdx  myoﬁbers showed an extensiveA. Cozzoli et al. / Pharmacolo
hat undergoes nuclear translocation. In line with previous ﬁndings
29], a high percentage of ﬁbers positive for activated NF-kB was
ound in GC muscle of vehicle-treated mdx  mice (60 ± 7%; N = 3/9).
nterestingly, a marked and signiﬁcant reduction of positive nuclei
as observed in enalapril-treated GC mdx  muscles. In fact the
ositivity was observed in only 28 ± 13.5% of ﬁbers in the 5 mg/kg
reated group (mean ± SD; p < 0.05 by Student’s t test) (Fig. 5 upper
anel).
.3. Effect enalapril on histopathology and biochemical markers
The GC and DIA muscles of vehicle-treated mdx  mice showed
emarkable morphological alterations with extensive areas of
ecrosis, and a wide presence of centronucleated ﬁbers, as a clear
ndex of degeneration–regeneration cycles. The architecture was
arkedly compromised due to irregular ﬁber shape and to the
resence of cluster of small regenerating ﬁbers, of mononuclear
nﬁltrates and of areas of non-muscle tissue (Fig. 5 – lower panel A,
).
The treatment with enalapril led to an amelioration of the
istological picture in both muscles, in term of a more regular tis-
ue architecture and signiﬁcant reduction of damaged areas vs.
ntreated ones (Fig. 5 lower panel C, D). In both muscles, the
orphometric analysis showed a signiﬁcant decrease of the area
f necrosis (Table 2). The decrease in necrosis was  similar to the
0–80% decrease observed in both muscles after PDN treatment
data not shown). In GC muscle an increase in the percent of nor-
al  peripherally nucleated ﬁbers vs. centronucleated ones was
bserved, supporting a decrease in the degeneration–regeneration
ycles. This was corroborated by the observation that centronu-
leated ﬁbers in enalapril-treated GC muscle also showed a trend
oward smaller area, while the opposite was observed in normal
bers (Table 2). Interestingly, in diaphragm, the decrease of necro-
is was accompanied by an increase in centronucleated ﬁbers; in
arallel a signiﬁcant increase of the area of both normal and cen-
ronucleated ﬁbers was observed (Table 2). This suggests a possible
ole of enalapril in reducing degeneration meanwhile enhancing
egeneration efﬁciency in a muscle-type speciﬁc manner. In both
uscles, the area covered by non-muscle tissue, and likely related
o ﬁbrosis was  only slightly but not signiﬁcantly reduced, sug-
esting minor effects of enalapril on pro-ﬁbrotic pathways. To
erify this hypothesis, the total level of TGF-1 has been mea-
ured by ELISA assay. As can be seen in Fig. 6 (upper panel),
o signiﬁcant changes were found in the levels of TGF-1 in
ig. 7. Effect of enalapil treatment on plasma level of creatine kinase and lactate
ehydrogenase of mdx mice. Plasma level of creatine kinase (CK) and lactate dehy-
rogenase (LDH) measured by standard spectrophotometric analysis. Each columns
s  the mean ± S.E.M. from 5 to 8 animals. No signiﬁcant statistical differences were
bserved between values of mdx  mice (either treated or not).esearch 64 (2011) 482– 492 489
GC muscle of mdx  mice treated with enalapril at either dosages.
Similarly, in diaphragm the TGF-1 level were 0.46 ± 0.06 pg/g
(n = 9) and 0.43 ± 0.1 pg/g (n = 5) in vehicle and 5 mg/kg treated
enalapril, respectively. In order to better evaluate the effect ofFig. 8. Effect of enalapril treatment on sarcolemmal ionic conductances and
mechanical threshold of EDL muscle ﬁbers of mdx mice. (A) Component ionic con-
ductances to chloride (gCl) and potassium (gK) ions of extensor digitorum longus
(EDL) muscle ﬁbers of Mdx  mice either untreated (+ vehicle) or treated with enalapril
at  1 mg/kg (Enal 1); enalapril at 5 mg/kg (Enal 5) or -methyl prednisolone at
1  mg/kg (PDN). Each column is the mean ± S.E.M. from 15 to 30 ﬁbers from 3 to
7  preparations. The ANOVA test for multiple comparison was signiﬁcant for both
gCl (F > 16; p < 0.0001) and gK (F = 3.7; p < 0.02). Bonferroni’s t test is as follows: *Sig-
niﬁcantly different with respect to untreated MDX  mice (p < 0.0001); §Signiﬁcantly
different with respect to WT  for either gCl (p < 0.0001) or gK (p < 0.02). (B) Effect
of  treatment with enalapril 5 mg/kg (Enal 5) and -methyl prednisolone (PDN) on
mechanical threshold of Extensor digitorum longus (EDL) muscle ﬁbers. The data,
expressed as mean ± S.E.M. from 10 to 34 values from 3 to 5 preparations (see also
Table 2), show the voltages for ﬁber contraction (mechanical threshold) at each
pulse duration in different experimental conditions and in particular in wildtype
(WT, open circles), vehicle-treated mdx mice (Mdx + vehicle, open squares), and
PDN (upside-down open triangles) or Enalapril treated (open triangles) mdx mice.
For  some data point the standard error bar is not visible being smaller than sym-
bol  size. The ﬁt of the experimental data lead to the calculation of rheobase voltage
values reported in the text.
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Table  3
Effect of Enalapril treatment on mechanical threshold of extensor digitorum longus (EDL) muscle ﬁbers of mdx  mice.
Experimental conditions 5 ms  10 ms  20 ms  50 ms  100 ms 200 ms 500 ms
WT −49.0 ± 0.5(10) −61.9 ± 0.7(12) −66.7 ± 0.7(11) −69.7 ± 0.4(14) −68.6 ± 0.6(15) −69.8 ± 0.5(14) −70.5 ± 0.4(16)
Mdx  + vehicle −53.4 ± 0.5(17) −62.9 ± 0.5(16) −69.1 ± 0.3(17) −76.3 ± 0.3(20) −76.4 ± 0.3(19) −76.6 ± 0.2(19) −76.8 ± 0.2(23)
Mdx  + Enal 5 −52.5 ± 0.9(16) −61.0 ± 1.1(15) −66.3 ± 0.7*(17) −73.3 ± 0.4*(25) −72.9 ± 0.5*(21) −73.2 ± 0.5*(23) −73.7 ± 0.3*(34)
Mdx  + PDN −53.3 ± 0.4(31) −59.9 ± 0.3*(29) −66.6 ± 0.2*(30) −73.4 ± 0.2*(33) −73.6 ± 0.2*(33) −73.4 ± 0.2*(32) −73.9 ± 0.2*(34)
The columns from left to right are as follows. Experimental conditions, the ﬁbers sampled are from extensor digitorum longus (EDL) muscles from mdx mice untreated
(Mdx  + vehicle) or treated with the test compounds: enalapril at 5 mg/kg (Enal 5) and -methylprednisolone (PDN). For each experimental group are shown the threshold
membrane potential values obtained with depolarizing command pulse of duration ranging from 5 up to 500 ms. The values are expressed as mean ± S.E.M. from the number
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00  ms  are signiﬁcantly different with respect to WT  ones. *Signiﬁcantly different 
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eactivity occurring in both central (by 63%) and peripheral nuclei
by 37%). The reactivity was generally less evident in GC muscles
rom enalapril treated mice (5 mg/kg) and in particular in centronu-
leated ﬁbers (35% over total positive myoﬁbers); however the
uantitative analysis of total reactivity showed that this trend was
ot statistical signiﬁcant, again supporting a minor anti-ﬁbrotic
ffect of enalapril at this pathology stage (Fig. 6, lower panel).
We next evaluated if the improved in vivo performance, the
eduction of muscle necrosis and the reduced markers of oxida-
ive stress were paralleled by an amelioration of the biochemical
arkers of pathology. The high plasma level of creatine kinase (CK)
s a clear diagnostic sign of dystrophic muscle damage. None of
he treatments exerted signiﬁcant reduction of plasma CK. Sim-
larly, no signiﬁcant changes were observed in the plasma level
f lactate dehydrogenase (LDH), taken as a marker of contraction-
nduced metabolic distress (Fig. 7). Then, all the values remained
igniﬁcantly higher than those of wt animals (data not shown).
.4. Effect of enalapril on functional myoﬁber parameters
Functional cellular parameters can be taken as biomarkers of
uscle state. A speciﬁc marker of spontaneous and/or exercise
nduced myoﬁber damage is the signiﬁcant reduction of the macro-
copic conductance to chloride ion (gCl). gCl is sensitive to the
irect action of pro-inﬂammatory cytokines; consequently, anti-
nﬂammatory drugs or partial increase in dystrophin level exert
rotective effects on this cellular index [26,28,29,33].  The treat-
ent with enalapril lead to a signiﬁcant and dose-dependent
ncrease in gCl values in EDL myoﬁbers. The recovery score for
his parameter was 69% and 90% in 1 and 5 mg  /kg treated mdx
DL, respectively (Fig. 8A). The effect observed was slightly lower
han that observed in PDN-treated EDL muscle (recovery score
5%) thus corroborating that it may  be due to the ability of blunt-
ng an inﬂammation-related mechanism. In addition, preliminary
esults suggest that muscle chloride channels can be a direct tar-
et of Ang-II action via activation of an AT1 receptor [35]. A
lear trend toward a dose-dependent increment of gCl was also
bserved in diaphragm as gCl was 1446 ± 86 S/cm2 (N/n = 5/43);
524 ± 82 S/cm2 (N/n = 4/40); 1632 ± 125 S/cm2 (N/n = 3/19) in
ehicle, 1 mg/kg and 5 mg/kg enalapril-treated, respectively. The
ess efﬁcacy in diaphragm vs. EDL muscle could be likely related
o the possible different mechanism underlying the impairment of
he chloride channel in the two muscle types [26,28]. No signiﬁcant
ffect of enalapril treatment was observed on potassium conduc-
ance (gK) in either EDL muscle (Fig. 8) or diaphragm (data not
hown).
The effects of enalapril were also evaluated on the alteration
f the voltage threshold for contraction (mechanical thresh-
ld, MT), a calcium-dependent electrophysiological index of
xcitation–contraction (e–c) coupling mechanism [28]. The alter-
tion of this parameter, along with that of cytosolic calcium
evel, can be fully contrasted by drugs able to directly act on thest 3–5 animals were sampled. In all mdx  groups, the threshold values from 50 to
espect to Mdx  + vehicle group by ANOVA and Bonferroni t’test correction (p < 0.05
channels that contribute to the enhanced sarcolemmal permeabil-
ity in mdx  myoﬁbers [19,36]. The threshold potential values of
enalapril-treated EDL mdx  ﬁbers were slightly, albeit signiﬁcantly,
shifted toward more positive potentials vs. those of untreated ones,
mostly at the long depolarizing steps (from 50 ms  ahead) (Table 3).
Then, a shift of the strength-duration curve toward more posi-
tive potentials was observed in enalapril-treated muscle (Fig. 8B).
The rheobase values calculated from the ﬁt were −72.2 ± 1.3 mV
and −75.6 ± 1.24 mV  for enalapril and vehicle-treated muscles,
respectively. The difference was not statistically signiﬁcant (t = 1.8;
p > 0.05). Both values were still highly signiﬁcantly different with
respect to that of wild-type myoﬁbers (−66.2 ± 0.47 mV;  p < 0.001).
The effect of 5 mg/kg enalapril almost overlapped that observed
with PDN and underlined a modest recovery score (around 35%)
on the calcium homeostasis. No effect of either drug was observed
on the time constant to reach the rheobase (data not shown). The
result is in line with the observation that other drugs acting as
pure anti-inﬂammatory compounds do not exert any improvement
in calcium homeostasis of mdx  myoﬁbers, and suggests that the
modest beneﬁt of both enalapril and PDN could be related to the
anti-oxidant effects, in relation to the possible cross-talk between
ROS and calcium handling mechanisms [20,26,33].
4. Conclusions
ACE inhibitors are a widely used class of drugs for cardiovas-
cular disorders due to their ability to reduce both short and long
term effects of Ang II on function and re-modelling of heart and
vascular system. Accordingly, ACE inhibitors are already clinically
used to contrast cardiomyopathy occurring in Duchenne patients,
and data from clinical trials corroborate the ability of these drugs
in prolonging survival [8,9]. The establishment of direct beneﬁ-
cial effect of this class of therapeutics at skeletal muscle level in
parallel with the clariﬁcation of their mechanism of action can
further reinforce their clinical use in DMD. In fact, data in the lit-
erature support a potential involvement of RAS in muscles of DMD
patients, with over-expression of angiotensin converting enzyme
and of AT-1 receptor, in parallel with TGF-1, in regenerating
muscle ﬁbers, ﬁbroblasts and inﬂammatory inﬁltrates [37]. This is
supported by recent evidence of the presence of several compo-
nents of RAS in myoﬁbers, corroborating an autocrine production
of Ang II in skeletal muscle, potentially triggered by mechanical
challenge [38], a critical issue for dystrophic muscle. In addition,
long term and indirect activation of systemic RAS, such as that
consequent to congestive heart failure, also plays a role in skele-
tal muscle atrophy, through direct action of Ang II in regulating the
two  ubiquitin ligases atrogin-1 and muscle ring ﬁnger-1 (MuRF-
1) [16,39].  Although direct evidence about involvement of RAS
in the murine pathology is not available, pre-clinical studies in
mdx  mice claimed a prominent role of Ang-II-TGF-pathway in
late occurring ﬁbrosis and failing regeneration [11]. Our results
favor a role of Ang-II in early inﬂammatory phases of muscular
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ystrophy, supporting a wider protective role of ACE inhibitors in
ystrophic muscle. Mostly, the results of our study evidenced the
bility of enalapril to exert protective effects on mouse strength,
hile signiﬁcantly reducing the production of ROS and the activa-
ion of NF-kB, pathways that play a key role in muscular dystrophy
18,19,23]. Our results are in line with various evidences show-
ng that Ang-II has pro-inﬂammatory actions and contributes to
nsulin resistance in myocytes via ROS-independent and dependent
athways, these latter involving a receptor and NF-kB-mediated
ctivation of NADPH oxidase [17,40,41].  Interestingly, Ang II has
een recently claimed to exert a wasting catabolic effect in mouse
keletal muscle via NADPH oxidase derived ROS [42], while losar-
an protects against disuse atrophy in rodent sarcopenia via a
GF-1 independent signaling which rather involves the activa-
ion of insulin-like growth factor 1 (IGF-1) pathways [43]. Then
t is feasible that in dystrophic pathology RAS may  contribute to
he early inﬂammatory microenvironment necessary to reinforce
he damaging later effects via TGF-1, meanwhile weakening the
GF-1-dependent regenerative program [12,13,44].  Accordingly, in
he present study we found a clear reduction of muscle necrosis
y enalapril, with minor, if any, effects on non-muscle tissue, TGF-
1 level and p-Smad 2/3 reactivity, supporting earlier actions vs.
he induction of ﬁbrosis. The possibility that enalapril also acts by
ontrasting functional ischemia cannot be ruled out, although the
odest recovery of resistance to exercise does not support this
iew.
However, in contrast with other anti-inﬂammatory compounds
26,33], enalapril did not reduce CK and LDH. The lack of effect on
K, also routinely observed in our experimental condition with PDN
27], has also been observed in long-term losartan treated mdx  mice
11]. In a strict sense CK level cannot be taken as a reliable outcome
easure for therapeutics as it might be inﬂuenced by the amount
f muscle/animal activity, or to other drug actions at sarcolemmal
evel.
Then, it is feasible to conclude that Ang II represents an early
pstream signals in triggering a chronic inﬂammatory state and
ystrophic muscle damage and its early blockade may  help in halt-
ng the establishment of auto-reinforcing signals. The results add
ew evidences about the potential interest of ACE inhibitors for
he therapy of DMD patients and support their early use. The PDN-
imilar proﬁle may  corroborate the combined use of the two  classes
f drugs in DMD  patients so to potentiate the beneﬁcial effects at
keletal muscle level, while reducing both spontaneous and PDN-
ggravated cardiomyopathy [10].
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